Hikma Pharmaceuticals
13 Hanover Square
London
W1S 1HL
United Kingdom
Tel: 44-0-20-7399-2760
Fax: 44-0-20-7399-2761
Website: http://www.hikma.com/
Email: media@hikma.com
115 articles about Hikma Pharmaceuticals
-
Despite a patent extension, Merck’s muscle relaxant reversal injection is now facing potential generic competition from Hikma Pharmaceuticals, which is seeking the FDA’s approval for a copycat version.
-
Guardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North Africa
1/8/2024
Guardant Health, Inc. and Hikma Pharmaceuticals PLC announced an agreement to promote Guardant Health’s portfolio of liquid and tissue biopsy tests for cancer screening, recurrence monitoring and tumor mutation profiling across all solid cancers in countries across the Middle East and North Africa.
-
CanariaBio and Hikma announce the signing of distribution and license agreement for oregovomab in MENA Region
10/10/2023
CanariaBio Inc. and Hikma MENA FZE, part of Hikma Pharmaceuticals PLC, announced the signing of distribution and license agreement for oregovomab in the Middle East and North Africa region.
-
Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North Africa
8/10/2023
Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform announces an exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC, a multinational pharmaceutical company for the Middle East and North Africa.
-
Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region
12/26/2022
Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announces a new exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, for toripalimab in the Middle East and North Africa.
-
Corcept Therapeutics Settles Patent Litigation with Hikma Pharmaceuticals
12/8/2022
Corcept Therapeutics Incorporated today announced that it has entered into an agreement with Hikma Pharmaceuticals USA Inc. ("Hikma") resolving patent litigation related to Korlym ®, Corcept’s medication for the treatment of patients with Cushing’s syndrome.
-
Arguments regarding the Purdue Pharma opioid settlement continue to be heard in court, Natera battles a class-action lawsuit, Walgreens is involved in a public nuisance suit and more.
-
Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals
4/29/2022
Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Bio-Thera Solutions and Hikma Pharmaceuticals Announce Exclusive Commercialization and License Agreement for BAT2206 in the US, a Proposed Biosimilar Referencing Stelara® (ustekinumab)
8/27/2021
Bio-Thera Solutions, Ltd. and Hikma Pharmaceuticals PLC announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal antibody that is a proposed biosimilar referencing Stelara®, in the United States.
-
Hikma resumes launch of generic Advair Diskus®
4/20/2021
Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline's Advair Diskus®1 in the US following US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021.
-
Hikma and Arecor Expand Collaboration
10/20/2020
Hikma Pharmaceuticals PLC and Arecor Limited announce they have entered into a new exclusive agreement to co-develop a ready-to-administer injectable medicine in the US through Hikma's affiliate, Hikma Pharmaceuticals USA Inc.
-
Hikma receives favourable court ruling for its generic Vascepa®
9/3/2020
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that the US Court of Appeals for the Federal Circuit today upheld a ruling by the US District Court for the District of Nevada finding that Hikma's generic version of Vascepa ®1 (icosapent ethyl) 1gm does not infringe any valid claim of six key Amar
-
Premier Inc. ProvideGx™ Program Partners with Hikma Pharmaceuticals to Secure the Supply of Two Drugs Essential for COVID-19 Patient Care
5/28/2020
Premier Inc., through its ProvideGx™ program, has partnered with Hikma Pharmaceuticals PLC to supply amiodarone and sterile water to healthcare providers, helping to stabilize the long-term supply of two medications vital for COVID-19 patient care.
-
Hikma launches employee matching donation campaign to support local US food banks and pantries
5/11/2020
Campaign will help address significant increase in demand caused by COVID-19 related job losses and furloughs
-
Hikma Ventures invests in Altoida, Inc., a predictive digital biomarker company using AI and AR to help predict brain diseases with up to 94% accuracy
5/4/2020
Hikma Pharmaceuticals PLC announces that its venture capital arm, Hikma Ventures has invested in Altoida, Inc. following the company's $6.3 million Series A round in 2019..
-
Hikma confirms favourable ruling in generic Vascepa® patent suit
3/31/2020
Hikma Pharmaceuticals PLC confirms that the United States District Court for the District of Nevada has ruled that Hikma's generic version of Amarin Corporation's Vascepa® 1 gm capsules does not infringe six United States Patents, as asserted by Amarin, because the asserted claims of these patents were held to be invalid.
-
Hikma Pharmaceuticals USA Inc. Extends Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP 30mg/mL, 1mL Fill/2mL Vials Due to the Potential Presence of Small Particulates
3/4/2020
Hikma Pharmaceuticals PLC, announces that its subsidiary Hikma Pharmaceuticals USA Inc. is voluntarily extending its previously-announced recall of certain lots of Ketorolac Tromethamine Injection USP 30mg/mL, 1mL fill/2mL vials to the medical facility and retail levels.
-
Hikma and Glenmark Pharmaceuticals Enter into Exclusive Licensing Agreement for Commercialising Ryaltris™ Seasonal Allergic Rhinitis Nasal Spray in the US
2/27/2020
Builds on Hikma's leading position in nasal sprays and strong specialty salesforce
-
Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt®
1/13/2020
This order by the U.S. Supreme Court ensures that the '610 patent will remain exclusive at least through November 2, 2027, absent further challenges from other parties.